The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.30
Bid: 3.20
Ask: 3.40
Change: 0.05 (1.54%)
Spread: 0.20 (6.25%)
Open: 3.25
High: 3.30
Low: 3.10
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

Thu, 03rd Oct 2013 11:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Thursday.

-------

FTSE 100 - Winners

Aviva shares, up 2.5%, are the biggest risers on the blue-chip index. The financial services provider announced Wednesday that it had completed the sale of its US operations to Athene Holding Ltd in a deal worth USD2.6 billion, some USD800 million more than previously announced.

J Sainsbury, up 1.2%, and Tesco, up 1%, are big gainers. The food retailers are rebounding from Wednesday's lows after investors reacted negatively to their trading statements. Sainsbury's is benefiting from Nomura increasing its price target to 370 pence from 350p. Similarly, Citigroup upgraded Tesco to Neutral from Sell, raising its price target to 350 from 285. However, Deutsche Bank, JP Morgan and Macquarie have all cut Tesco's price target. Both companies are trading close to pre-announcement levels.

BP climbs 0.9% after the Financial Times reported Thursday that it had reached a milestone in its legal battle to limit its compensation settlement for the 2010 Deepwater Horizon disaster. The FT announced that the oil and gas company had received a favourable ruling from a US court. The court on Wednesday night approved an injunction to stop payments to businesses that had not "experienced actual injury traceable to loss" from the Deepwater Horizon accident, overturning an earlier decision. The ruling may improve BP's chances of preventing the cost of the settlement rising beyond double its original estimate of USD7.8 billion.

-------

FTSE 100 - Losers

Sports Direct International, down 2%. The company announced that Chief Executive Officer Dave Forsey and Group Finance Director Bob Mellors, exercised options granted to them under the company's executive bonus share scheme, by acquiring 1.0 million shares and then each selling 950,000 them at a price of 680.0 pence per share on Wednesday. The 50,000 shares each retained by Forsey and Mellors are their only holdings in sporting good company, representing 0.01% stakes.

William Hill falls 1.5% after the company warned that gross win margins in sports betting were below the year before. In its interim management statement for the 13 weeks ended October 1, the company said its overall quarterly performance was impacted by quiet July trading in Retail together with lower results-linked gross win margins in the quarter. Analysts at Numis remain upbeat, but note that profits have fallen short of expectations by GBP20 million.

Standard Chartered drops 0.9% in the aftermath of Numis downgrading its recommendation. Numis cuts Standard Chartered's recommendation to Hold from Add, decreasing its price target to 1,500 pence from 1,780p. The downgrades are made as Numis reduces its 2013-2014 forecasts for Standard Chartered by 5%. Currency depreciation across a large number of Standard Chartered's operational territories has hit the international banking group hard. Numis estimates that currency alone reduces estimates by 2%. Weak third-quarter financial markets volumes also are to blame.

-------

FTSE 250 - Winners

BTG, up 1.4%. The healthcare company raised its full-year revenue guidance due to recent acquisitions it has made and said its performance the first half of the year had met its expectations. It now expects revenues in the year to March 31, 2014 to be between GBP275 million and GBP285 million, up from previous guidance of between GBP235 million and GBP245 million, after making progress in integrating the targeted therapies division of Nordion Inc., and EKOS Corporation, deals that it completed in July. In a trading update, the company said new varicose vein treatment Varisolve is still progressing through a new drug application review in the US, and it is pushing ahead with preparations for a commercial launch in the first six months of the 2014 calendar year.

-------

FTSE 250 - Losers

Ophir Energy, down 4%. The oil-and-gas producer said Wednesday that it had successfully completed the Pweza-3 appraisal well and flow test in Block 4, Tanzania. However, the stock falls for a second day as the market has little interest in appraisals until there are further farm-out announcements, says Cannacord analyst Charlie Sharp. A farm-out announcement is an agreement to outsource production of discoveries, rather than simply reporting the discoveries.

-------

AIM - Winners

Phorm Corporation, up 64%. The company has been boosted after it said that it had launched operations of its advertising platform in mainland China. The internet personalisation technology company has begun a nationwide opt-in process, and in its first week of operations has seen an average of 4.3 million users a day. It said that it was in negotiations with publishers and advertisers and had begun the commercialisation process of its operations. In the coming months the company will start its test campaigns, it said, before moving to commercial operations.

Desire Petroleum climbs 31%. Falkland Oil and Gas Limited and Desire Petroleum PLC have announced that they have reached an GBP61 million agreement for Falkland to acquire the entire share capital of Desire in exchange for FOGL shares. The oil and gas exploration and development companies, both operating in the Falkland Island Basins, said that both boards believe the deal will diversify the activities of both companies and improve finances. Following the deal, FOGL shareholders will own 60% of the combined group share capital with Desire shareholders owning the remaining 40%.

Evocutis shares jump 24% as the company rebounds from Wednesday's lows. Evocutis was a big faller Wednesday as it announced that it is to convene a general meeting on October 28 after its net assets fell to less than half of its share capital. The company said that it was no longer in discussions with potential offerers in relation to a merger or sale of the company. Evocutis shares are still a long way off pre-announcement levels.

Quoram is up 16% despite making a GBP2.0 million pretax loss for the year to June 30, compared with a loss of GBP728,000 last year. The company has announced that it is confident about the prospects for its first investment since making the transition from oil-and-gas explorer to investing company, AIM-listed Plant Health Care PLC. Quoram said Plant Health Care, which makes products that increase crop yields, could benefit from the rise in the world's population to over seven billion people and the subsequent increase in demand for food.

Alecto Minerals, up 16%. The African-focussed multi-commodity exploration and development company is widely expected to complete the acquisition of AME West Africa from Savannah Resources in the next few days.

Byotrol is up 9.8 % after it said it has entered into an agreement to acquire all of the issued shares that it does not currently own in its consumer products joint venture, Byotrol Consumer Products Limited. Byotrol Consumer Products was established in 2007 as a joint venture between Byotrol and ?What If! Innovation Capital Nominees Limited.

Varirx is up 8.1% on the back of the news that it has filed a Phase IB/dose escalation study for its anti-cancer therapeutic, VAL201. This filing is required before approval is able to be granted. ValiRx said the trial on prostate cancer patients will be a first in-man study with real patients and will not require health volunteers. A first in-man study is a clinical trial where a medical procedure, previously developed and assessed through in vitro or animal testing, or through mathematical modelling is tested on human subjects for the first time.

-------

AIM - Losers

Albemarle & Bond, down 11%, continues to fall, albeit at a slower rate, after it announced Wednesday that it was in talks with its lenders about solving potential breaches of its debt covenants later this year after discussion with its largest shareholder about an equity raising failed.

Noricum Gold is down 11% as investors react badly to the news that it has raised GBP2 million to develop its Rotgulden Gold and Precious Metals project in Austria. The gold exploration and development company said it raised the cash via an oversubscribed placing of 200 million new ordinary shares, diluting the price of existing shares.

-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
24 Aug 2023 11:06

ValiRx interim loss widens as costs increase; hails Inaphaea progress

(Alliance News) - ValiRx PLC on Thursday reported an increased half-year loss amid higher costs, as it continued to focus on building its science-focused portfolio.

Read more
24 Aug 2023 09:59

ValiRx shares jump as H1 losses shrink

(Sharecast News) - Shares in ValiRx jumped nearly on Thursday after the biotech posted results for its first half, in which losses per share shrunk by a third.

Read more
14 Aug 2023 09:53

ValiRx subsidiary Inaphaea signs deal with Agility Life Sciences

(Sharecast News) - Life science company ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has entered a collaborative services agreement with Agility Life Sciences.

Read more
14 Aug 2023 08:52

ValiRx signs collaborative services agreement with Agility

(Alliance News) - ValiRx PLC on Monday said its wholly-owned subsidiary, Inaphaea BioLabs Ltd, has entered into a collaborative services agreement with Agility Life Sciences Ltd.

Read more
19 Jul 2023 09:39

IN BRIEF: ValiRx subsidiary secures contract with UK biotech firm

ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphea BioLabs Ltd will partner with an unnamed UK-based biotechnology company on a phenotypic assay to investigate anti-cancer properties using patient-derived cells from Inaphea's biobank. Adds Inaphea has started internal studies on ValiRx assets s VAL301 and Cytolytix CLX001. "This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023," ValiRx says.

Read more
28 Jun 2023 20:25

TRADING UPDATES: All Things Considered raises funds to buy Sandbag

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News:

Read more
21 Jun 2023 15:43

UK shareholder meetings calendar - next 7 days

Thursday 22 June 
Alphawave IP Group PLCAGM
Angling Direct PLCAGM
Anglo Asian Mining PLCAGM
boohoo Group PLCAGM
Braime Group PLCAGM
Card Factory PLCAGM
Ergomed PLCAGM
Falcon Oil & Gas LtdAGM
Futura Medical PLCAGM
Good Energy Group PLCAGM
Grand Vision Media Holdings PLCAGM
Longboat Energy PLCAGM
MaxRets Ventures PLCAGM
Pathfinder Minerals PLCAGM
RBG Holdings PLCAGM
Robinson PLCAGM
Sanderson Design Group PLCAGM
Team17 Group PLCAGM
Trellus Health PLCAGM
Whitbread PLCAGM
Friday 23 June 
Cadogan Petroleum PLCAGM
Mears Group PLCAGM
Non-Standard Finance PLCAGM
Ocean Harvest Technology Group PLCAGM
Oxford Biomedica PLCAGM
Pelatro PLCAGM
Petrofac LtdAGM
Princess Private Equity Holding LtdAGM
Rathbones Group PLCGM re agreement regarding all-share combination with Invested Wealth & Investment Ltd
Supply@Me Capital PLCGM re open offer warrant holders
Vietnam Enterprise Investments LtdAGM
VPC Specialty Lending Investments PLCAGM
Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 11:51

IN BRIEF: ValiRx subsidiary to supply cell-based assays to OncoBone

ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphaea Biolabs Ltd enters agreement with OncoBone Ltd. Says OncoBone clients will be able to access Inaphaea services. Notes Inaphaea is now confirmed as a cell-based assay supplier to OncoBone. Adds Inaphaea's services are now listed on scientist.com, a database website used by biotechnology and pharmaceutical companies.

Read more
16 Jun 2023 11:14

ValiRx terminates collaboration with Hokkaido University

(Sharecast News) - Life science company ValiRx has officially concluded its evaluation agreement with Hokkaido University, it announced on Friday.

Read more
16 Jun 2023 10:29

AIM WINNERS & LOSERS: Marlowe up on report of potential division sale

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
16 Jun 2023 09:09

ValiRx shares drop after cancer drug research dropped

(Alliance News) - ValiRx PLC shares fell on Friday, after it ended its evaluation agreement with Hokkaido University to research a potential drug.

Read more
16 Jun 2023 08:47

LONDON MARKET OPEN: Stocks head higher as pound tops USD1.28 again

(Alliance News) - Stock prices in London opened higher on Friday, taking their cue from Asian and US equities, while investors weighed recent interest rate decisions.

Read more
14 Jun 2023 14:37

ValiRx acquires assets of in-liquidation Imagen Therapeutics

(Sharecast News) - Life science company ValiRx has successfully completed the acquisition of the scientific assets of Imagen Therapeutics, it announced on Wednesday.

Read more
14 Jun 2023 11:35

ValiRx buys Imagen's scientific assets for cancer screening services

(Alliance News) - ValiRx PLC on Wednesday said it acquired the scientific assets of Imagen Therapeutics Ltd from its appointed liquidators for GBP170,000.

Read more
7 Jun 2023 12:44

ValiRx expands cancer research agreement with University of Barcelona

(Alliance News) - ValiRx PLC on Wednesday said it has expanded a pre-existing agreement with the University of Barcelona to test additional molecules as possible drugs for cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.